Tumor-Suppressing Effects of miR-141 in Human Osteosarcoma
32
Citation
36
Reference
10
Related Paper
Citation Trend
Keywords:
Pathogenesis
MicroRNA (miRNA) is an important type of non-coding RNAs with both physiological and pathological functions in human beings. Aberrant expression of miRNAs has been found in tumor tissues and the expression profile of certain groups of miRNAs is now emerging as bio-marker for cancer. It has been confirmed that miRNAs can exert oncogenic or tumor-suppressive functions through repressing the expression of their target genes which play different roles in tumorigenesis. The identification of oncogenic or tumor-suppressive miRNAs allows potential applications of these miRNAs as targets for cancer chemotherapy. In this review, we summarized the well-known cancer-related miRNAs reported in recent years and the roles they played in tumorigenesis and progression by targeting specific genes. Strategies developed to modulate the function or expression of the dysregulated miRNAs are also reviewed with recent examples illustrating their potential applications in cancer chemotherapy. Keywords: MicroRNA, oncogenic, tumor-suppressive, up-regulation, down-regulation, tumorigenesis, cancer chemotherapy.
Cite
Citations (19)
MicroRNA (miRNA ) 是在长度的 2123 核苷酸的小非编码的 RNA 分子的簇，它在 post-transcriptional 水平控制目标基因的表达式。最近的研究显示了 miRNA 在 carcinogenesis 起一个必要作用，例如影响房间生长，区别， apoptosis，和房间周期。现在，涉及 carcinogenesis 的 miRNA 的多重答应角色正在出现，并且 miRNA 仔细联系到 epithelialmesenchymal 转变(EMT ) 的进程，这被显示出，癌症干细胞(CSC ) 的规定，肿瘤侵略和移植的开发。miRNA 也充当稳定地在浆液表示的 biomarker 并且为各种各样的癌症的分子的目标治疗提供新目标。这评论的目的是在 carcinogenesis 说明 miRNA 的新角色并且在癌症加亮 miRNA 的新前景临床的申请，例如在血清学的诊断和分子目标的治疗学。
Cite
Citations (0)
To study the relationship between expression of bladder cancer-associated protein (BLCAP) and malignancy of osteosarcoma.SABC method was applied to study the expression of BLCAP protein in osteosarcoma, according to clinical results, to analyze the prognosis value of BLCAP protein in osteosarcoma.The positive rate of BLCAP protein in primary osteosarcoma was 65.6%,much higher than that in recurrent osteosarcoma, which was 25.0%.It may be helpful for evaluating the prognosis of osteosarcoma to study the relationship between expression of BLCAP protein and malignancy of osteosarcoma.
Cite
Citations (6)
Objective to find resistant and sensitive osteosarcoma tumor tissue samples,so that to prepare for further looking for differences in protein.Methods Obtain the tissue of patients with osteosarcoma,osteosarcoma cells isolated and cultured in vitro drug sensitivity test cells,so as to identify drug-resistant and sensitive osteosarcoma tissue samples.Results Detection curve of osteosarcoma cells to various chemotherapy drugs and Found resistant and sensitive osteosarcoma tissue samples.Conclusion Osteosarcoma has different sensitivity to various chemotherapeutic drugs,Cisplatin is further appropriate drugs to look for differences in protein research.
Chemosensitivity assay
Chemotherapeutic drugs
Cite
Citations (2)
Introduction: Osteosarcoma usually originates in the metaphyseal region of long bone, but may also arise in the diaphyseal of long bone. Diaphyseal osteosarcoma is a rare cases account for <10% of all osteosarcoma. In some cases two or more osteosarcoma lesions are seen in the same patient, at the same time (Synchronous osteosarcoma). It’s unusual condition of osteosarcoma, they are found at a frequency of about 1–3% osteosarcoma cases.
Cite
Citations (0)
Cases of unusual osteosarcoma comprising parosteal osteosarcoma, intraosseous well differentiated osteosarcoma, postradiation osteosarcoma, epithelioid osteosarcoma, and MFH-like osteosarcoma were reported. They were apparently differed from conventional osteosarcoma in the point of biologic activity and prognosis. Osteosarcoma is, therefore, considered as a heterogeneic tumor. It is important to make an exact diagnosis and to make an appropriate treatment depending on the diagnosis.
Cite
Citations (0)
Circular RNA
Cite
Citations (22)
Metachronous osteosarcomas (MOS) are currently defined as tumors that arise in a way and site unusual for typical metastasis. In this article, we reviewed the recent literature on the occurrence of metachronous osteosarcoma and presented a case from our center. Our patient, a 10-year-old girl, presented with metachronous osteoblastic osteosarcoma of the left distal femur ∼5 years after the successful treatment for osteosarcoma of the right distal femur. Even after several relapses, complete remission (CR) was achieved after the first osteosarcoma and after the metachronous osteosarcoma. The literature research revealed that metachronous osteosarcoma occurs in 3.4 to 5.4% of osteosarcoma patients. The time interval between the diagnosis of the initial osteosarcoma and the metachronous tumor ranged from 0.2 to 14.3 years (median 2.5 y). MOS appears to have differences in localization and metastatic spread, as well as a different survival pattern compared with primary osteosarcoma and osteosarcoma recurrence. Survival (median 4.3 y, range 0 to 24.6 y) appears to be associated with the time interval to diagnosis of MOS. In particular, early MOS (<24 mo after primary diagnosis) seem to have a poorer prognosis. Therefore, the occurrence of MOS at oncological unusual sites should be considered as a differential diagnosis in osteosarcoma survivors.
Cite
Citations (2)
Abstract A new class of regulatory molecules known as microRNAs (miRNAs) is redefining our understanding of the molecular pathways associated with tumorigenesis. These miRNAs are small noncoding RNA (ncRNA) sequences with potent regulatory potential. The aberrant expression of miRNAs has been associated with the development of various tumors. It has been suggested that miRNAs can both regulate and act as tumor‐suppressor genes and oncogenes. Our understanding of the role of miRNAs in head and neck tumorigenesis is in its infancy. However, several recent studies have revealed extensive dysregulation of miRNA in head and neck tumors and have highlighted the potential of certain miRNAs to act as diagnostic and prognostic markers and targets for new therapeutic agents. The intent of this review is to discuss and summarize current findings that point to a significant role for miRNAs in head and neck tumorigenesis. © 2010 Wiley Periodicals, Inc. Head Neck, 2010
Cite
Citations (65)